FNCHQ.US Finch Therapeutics Group, Inc.

Healthcare Biotechnology USA Stocks
10.35 USD
Close of Nov 5, 2026
5.60 16.10
Market cap
USD 16.6M
P/E
-
P/B
1.14x
ROE
-152.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is FNCHQ.US undervalued?

Graham number

The Graham number of Finch Therapeutics Group, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Finch Therapeutics Group, Inc. fundamental analysis

No fundamental analysis for Finch Therapeutics Group, Inc. yet.

Finch Therapeutics Group, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease…

Full company profile